Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NMRA

Neumora Therapeutics Inc

Dec 26 • 04:00PM ET

11.34

Dollar change +0.71
Percentage change 6.68	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: IWM VTI VXF IWO SCHA VTWO IBB XPH IHE VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.85	Insider Own	65.74%	Shs Outstand	160.48M	Perf Week	11.39%
Market Cap	1.83B	Forward P/E	-	EPS next Y	-1.64	Insider Trans	-0.21%	Shs Float	55.35M	Perf Month	17.27%
Income	-293.70M	PEG	-	EPS next Q	-0.44	Inst Own	29.79%	Short Float	19.57%	Perf Quarter	-13.30%
Sales	0.00M	P/S	-	EPS this Y	55.65%	Inst Trans	6.76%	Short Ratio	9.95	Perf Half Y	23.26%
Book/sh	2.00	P/B	5.67	EPS next Y	-1.71%	ROA	-65.46%	Short Interest	10.83M	Perf Year	-35.24%
Cash/sh	2.12	P/C	5.35	EPS next 5Y	-	ROE	-70.48%	52W Range	8.33 - 21.00	Perf YTD	-33.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-91.57%	52W High	-46.00%	Beta	3.16
Dividend TTM	-	Quick Ratio	10.98	Sales past 5Y	0.00%	Gross Margin	-	52W Low	36.13%	ATR (14)	0.77
Dividend Ex-Date	-	Current Ratio	10.98	EPS Y/Y TTM	-80.83%	Oper. Margin	-	RSI (14)	56.56	Volatility	9.15% 6.32%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	23.49
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-30.90%	Payout	-	Rel Volume	0.70	Prev Close	10.63
Sales Surprise	-	EPS Surprise	-15.24%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.09M	Price	11.34
SMA20	9.34%	SMA50	-0.88%	SMA200	-1.32%	Trades		Volume	762,381	Change	6.68%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
01:54PM	Loading…
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
11:28AM	Loading…
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
07:00AM	Loading…
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fust Matthew K	Director	Oct 18 '24	Option Exercise	5.29	14,049	74,309	34,149	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Option Exercise	6.81	7,739	52,730	27,839	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Sale	17.03	14,049	239,319	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Sale	17.01	7,739	131,643	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Proposed Sale	17.03	14,049	239,319		Oct 18 04:01 PM
Fust Matthew K	Director	Oct 17 '24	Proposed Sale	17.01	7,739	131,643		Oct 17 04:26 PM
Lenz Robert A.	Head of R&D	Oct 10 '24	Sale	15.09	8,260	124,603	314,706	Oct 11 04:10 PM
Lenz Robert A.	Head of R&D	Oct 09 '24	Sale	15.01	5,563	83,507	322,966	Oct 11 04:10 PM
Lenz Robert A.	Officer	Oct 10 '24	Proposed Sale	15.09	8,260	124,603		Oct 10 04:30 PM
Lenz Robert A.	Officer	Oct 09 '24	Proposed Sale	15.01	5,563	83,507		Oct 09 04:10 PM
Lenz Robert A.	Head of R&D	Sep 17 '24	Sale	11.81	30,788	363,736	339,205	Sep 19 04:35 PM
Lenz Robert A.	Head of R&D	Sep 18 '24	Sale	12.09	10,676	129,091	328,529	Sep 19 04:35 PM
Lenz Robert A.	Officer	Sep 18 '24	Proposed Sale	12.09	10,676	129,091		Sep 18 04:27 PM
Lenz Robert A.	Officer	Sep 17 '24	Proposed Sale	11.81	30,788	363,734		Sep 17 04:37 PM
Lenz Robert A.	Head of R&D	Sep 12 '24	Sale	11.43	32,948	376,665	369,993	Sep 16 04:05 PM
Lenz Robert A.	Officer	Sep 12 '24	Proposed Sale	11.43	32,948	376,665		Sep 12 05:18 PM
Pinto Joshua	Chief Financial Officer	Aug 27 '24	Sale	11.39	15,693	178,806	138,965	Aug 27 05:58 PM
Pinto Joshua	Chief Financial Officer	Aug 26 '24	Sale	11.78	31,642	372,588	154,658	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 22 '24	Sale	11.63	28,496	331,468	210,469	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 23 '24	Sale	11.59	24,169	280,005	186,300	Aug 26 06:17 PM
Pinto Joshua	Officer	Aug 22 '24	Proposed Sale	11.90	100,000	1,190,000		Aug 22 09:48 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NMRA

Neumora Therapeutics Inc

Upgrade your FINVIZ experience